Coder and GlobalLogic Partner to Accelerate AI Development in the Enterprise

Coder and GlobalLogic Partner to Accelerate AI Development in the Enterprise Strategic alliance will empower enterprise development teams with secure, scalable infrastructure for AI-assisted software delivery GlobeNewswire December 17, 2025 AUSTIN, Texas, Dec. 17, 2025 (GLOBE NEWSWIRE) — Coder, the AI development infrastructure leading the transition to autonomous coding, and GlobalLogic, a Hitachi Group Company […]

Abcourt Presents Operations Update for November 2025 in the Development of the Sleeping Giant Mine

Abcourt Presents Operations Update for November 2025 in the Development of the Sleeping Giant Mine GlobeNewswire December 17, 2025 ROUYN-NORANDA, Quebec, Dec. 17, 2025 (GLOBE NEWSWIRE) — Abcourt Mines Inc. (“Abcourt” or the “Corporation“) (TSX Venture: ABI) (OTCQB: ABMBF) is pleased to present an update on the November development work at the Sleeping Giant Mine,

Secura Bio Announces NCCN(R) Duvelisib (COPIKTRA(R)) Update to Clinical Practice Guidelines in Oncology for Cutaneous T-Cell Lymphoma (CTCL), Including Mycosis Fungoides and Sezary Syndrome

Secura Bio Announces NCCN(R) Duvelisib (COPIKTRA(R)) Update to Clinical Practice Guidelines in Oncology for Cutaneous T-Cell Lymphoma (CTCL), Including Mycosis Fungoides and Sezary Syndrome GlobeNewswire December 17, 2025 BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) — Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced that duvelisib

Addition Therapeutics Announces $100 Million in Funding and Significant Progress Advancing Mission to Fulfill Promise of Genomic Medicine for Chronic and Rare Diseases

Addition Therapeutics Announces $100 Million in Funding and Significant Progress Advancing Mission to Fulfill Promise of Genomic Medicine for Chronic and Rare Diseases GlobeNewswire December 17, 2025 All-RNA, non-viral, LNP-based PRINT(TM) platform is designed to develop safer, durable, one-time therapies for a broad range of unmet needs Addition is advancing a robust pipeline of PRINTed

Baker Hughes to Supply Advanced Artificial Lift Solutions to Enhance Production in Kuwait Oil Company Fields

Baker Hughes to Supply Advanced Artificial Lift Solutions to Enhance Production in Kuwait Oil Company Fields GlobeNewswire December 17, 2025 Leucipa(TM), FusionPro(TM) integration will optimize ESP operations Agreement follows third-quarter award for advanced wireline, perforation technology HOUSTON and LONDON, Dec. 17, 2025 (GLOBE NEWSWIRE) — Baker Hughes (NASDAQ: BKR), an energy technology company, announced Wednesday

EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference

EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire December 17, 2025 WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) — EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and

Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference

Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire December 17, 2025 BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to deliver a corporate presentation at the 44th Annual J.P. Morgan Healthcare

Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers

Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers GlobeNewswire December 17, 2025 Preliminary Phase 1b data is in line with Phase 1a data reported at the European Society of Medical Oncology in September 2025 Combined disease control rate of 90% across both Phase 1a and Phase 1b

CMR Surgical secures 510(k) clearance of its Versius Plus robotic surgical system

CMR Surgical secures 510(k) clearance of its Versius Plus robotic surgical system GlobeNewswire December 17, 2025 16 December 2025 CMR Surgical secures 510(k) clearance of its Versius Plus robotic surgical system Regulatory clearance of CMR's most advanced system paves the way for upcoming US commercial launch Strong clinical interest received from US surgeons nationwide for

Simply Good Foods to Report First Quarter Fiscal Year 2026 Financial Results on Thursday, January 8, 2026

Simply Good Foods to Report First Quarter Fiscal Year 2026 Financial Results on Thursday, January 8, 2026 GlobeNewswire December 17, 2025 DENVER, Dec. 17, 2025 (GLOBE NEWSWIRE) — The Simply Good Foods Company (NASDAQ: SMPL) (“Simply Good Foods” or the “Company”), a leader in the Nutritional Snacking category, today announced it will report financial results

Scroll to Top